EYPT SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

EyePoint Announces Strategic Prioritization, Workforce Reduction, and Focus on DURAVYU for DME Following Wet AMD Trial Results

Oct 19, 2026

8-K

EyePoint Announces Topline Results from LUCIA Phase 3 Trial of DURAVYU in Wet AMD and Provides DME Program Update

Oct 19, 2026

8-K

EyePoint Pharmaceuticals Reports LUGANO Phase 3 Clinical Trial Results for DURAVYU in Wet AMD

Sep 10, 2026

8-K

EyePoint Announces Topline Data from LUGANO Phase 3 Clinical Trial for DURAVYU in Wet AMD

Aug 17, 2026

8-K

EyePoint Reports Second Quarter 2026 Financial Results and Clinical Development Updates

Aug 5, 2026

8-K

EyePoint Completes Enrollment of Phase 3 COMO and CAPRI Trials for DURAVYU™ in Diabetic Macular Edema

Jul 30, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

November 2025 ATM

Nov 6, 2025

424B5

REGISTERED OFFERING

Oct 15, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: J.P. Morgan, Jefferies, Citigroup, Guggenheim Securities

Oct 14, 2025

424B5

SHELF OFFERING | Shares amount: 12,727,273 | Share price: $11.00 | Offering amount: $140,000,003.00 | Bank: J.P. Morgan, Citigroup, Guggenheim Securities

Oct 30, 2024

424B5

.00 | Offering amount: $100,000,000.00 | Bank: J.P. Morgan, Citigroup, Guggenheim Securities

Oct 28, 2024

424B5

11,764,706 Shares

Dec 7, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 5, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Oct 14, 2025

S-3ASR

October 2025 SHELF

Oct 14, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 7, 2025

S-8

Registration

Aug 8, 2024

S-3

SHELF | ATM | Offering amount: $400,000,000.00 EFFECTIVE

Aug 8, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 9, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FEDERATED HERMES, INC. (Filed by)

Nov 4, 2026

SCHEDULE 13G/A

VANGUARD CAPITAL MANAGEMENT LLC (Filed by)

Oct 30, 2026

SCHEDULE 13G

TANG CAPITAL MANAGEMENT LLC (Filed by)

Oct 27, 2026

SCHEDULE 13G/A

FEDERATED HERMES, INC. (Filed by)

Oct 7, 2026

SCHEDULE 13G

Janus Henderson Group Ltd. (Filed by)

Sep 8, 2026

Elston George (Reporting)

Aug 24, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 19, 2024

CORRESP

Form CORRESP - Correspondence

Aug 14, 2024

LETTER

Form UPLOAD - SEC-generated letter

Aug 14, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 31, 2023

CORRESP

Form CORRESP - Correspondence

Oct 26, 2023

LETTER

Form UPLOAD - SEC-generated letter

Oct 25, 2023

EyePoint Pharmaceuticals, Inc. EYPT · SEC Filings